Established immune markers nevertheless protect their relevance for clinical decision-generating in breast cancer treatment with even prolonged meanings. Estrogen receptor (ER) stage shouldn't only be classified in positive or adverse. Lower ER amounts ≤10% of labeled cells needs to be dealt with in another way (LoE 1a/A/AGO++). Tumors with https://robertn418els5.azuria-wiki.com/user